장마감
로그인 회원가입
HROW
HROW
Harrow Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$37.46
-0.99 ▼ -2.57%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$37.46
+0.00 +0.00%

하로우(HROW) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$1.4B
스몰캡
P/E
-
배당수익률
없음
52주 위치
34%
저점 +31% · 고점 -32%
애널리스트
적극 매수
B
Fundamental health
vs. Drug Manufacturers - Specialty & Generic 소형주
수익성 ⓘ
Top 30%
성장 ⓘ
Top 34%
밸류에이션 ⓘ
Top 15%
재무 안정 ⓘ
Top 60%
Index ⓘ RUTP/E ⓘ -EPS (ttm) ⓘ -0.41Insider Own ⓘ 15.73%Shs Outstand ⓘ 37.3MPerf Week ⓘ -15.73%
Market Cap ⓘ 1.40BForward P/E ⓘ 16.04EPS next Y ⓘ 904.3%Insider Trans ⓘ -3.11%Shs Float ⓘ 31.4MPerf Month ⓘ -9.73%
Enterprise Value ⓘ 1.60BPEG ⓘ -EPS next Q ⓘ -0.18Inst Own ⓘ 57.78%Short Float ⓘ 21.79%Perf Quarter ⓘ -5.64%
Income ⓘ -0.01BP/S ⓘ 5.2EPS this Y ⓘ 266.07%Inst Trans ⓘ -0.33%Short Ratio ⓘ 8.24Perf Half Y ⓘ -15.76%
Sales ⓘ 0.27BP/B ⓘ 48.63EPS next 5Y ⓘ -ROA ⓘ -3.82%Short Interest ⓘ 6.84MPerf YTD ⓘ -23.55%
Book/sh ⓘ 0.77P/C ⓘ 14.75EPS past 3/5Y ⓘ 35.17% -1.53%ROE ⓘ -35.14%52W High ⓘ -31.7% ($54.85)Perf Year ⓘ 3.51%
Cash/sh ⓘ 2.54P/FCF ⓘ 97.71Sales past 3/5Y ⓘ 45.39% 40.99%ROIC ⓘ -4.55%52W Low ⓘ 31.25% ($28.54)Perf 3Y ⓘ 71.99%
Dividend Est. ⓘ -EV/EBITDA ⓘ 33.18EPS Y/Y TTM ⓘ 34.06%Gross Margin ⓘ 74.11%Volatility(W/M) ⓘ 5.75% 5.38%Perf 5Y ⓘ 328.11%
Dividend TTM ⓘ -EV/Sales ⓘ 5.96Sales Y/Y TTM ⓘ 26.22%Oper. Margin ⓘ 10.47%ATR (14) ⓘ 2.33Perf 10Y ⓘ 836.5%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.3EPS Q/Q ⓘ -49.39%Profit Margin ⓘ -5.57%RSI (14) ⓘ 37.83Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 2.48Sales Q/Q ⓘ -7.59%SMA20 ⓘ -12.61% ($42.87)Beta ⓘ 0.29Target Price ⓘ $67.75
Payout ⓘ -Debt/Eq ⓘ 10.47Earnings ⓘ 2026/5/11SMA50 ⓘ -3.28% ($38.73)Rel Volume ⓘ 0.62Prev Close ⓘ $38.45
Employees ⓘ 373LT Debt/Eq ⓘ 10.44EPS/Sales Surpr. ⓘ -85.65% -15.69%SMA200 ⓘ -8.88% ($41.11)Avg Volume(3M) ⓘ 0.83MPrice ⓘ $37.46
IPO ⓘ 2007/4/24Option/Short ⓘ Yes/YesTrades ⓘ 8095Volume ⓘ 516,645Change ⓘ -2.57%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $44M (YoY -8%) · 순이익 $-28M (YoY -55%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Harrow Inc (HROW) Investment Analysis

What kind of company is Harrow Inc?

하로우(HROW) 초고성장주
Healthcare · Drug Manufacturers - Specialty & Generic
Healthcare Stocks

👁️ Harpoon HROW is a US specialty pharmaceutical company focused on ophthalmology (eye care). Its core business is the development and commercialization of ophthalmic pharmaceuticals, and through ImprimisRx, its ophthalmic-focused compounding business, it supplies prescription eye drops and compounded products. The company is characterized by its concentration of resources in ophthalmology, a specific therapeutic area, allowing it to rapidly expand its portfolio of commercialized products.

Learn more about Harrow Inc →
Market Cap
$1.4B
Approx. KRW 1.9 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank2396
Employees373people
IPO2007/04/24
Current Price$37.46 ≈ 51,320원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 11일 (월) · 장 마감 후 EPS -85.7% 매출 -15.7%
🔔 Earnings release 2026년 3월 2일 (월) · 장 마감 후 EPS -53.8% 매출 -1.0%

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
10.5%
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median 8.8% · Top 41%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
-5.6%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
74.1%
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median 57.7% · Top 18%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-35.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-3.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-4.5%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
10.47
✓ Danger level
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
2.48
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.30
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$67.75
현재가 대비 +80.9%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
16.04배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
내년 EPS 예상 성장률
+904.3%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-89.0%
평균 서프라이즈
2026.05.11
하회
실적 $-0.74 · 예상 $-0.33 -124.2%
2026.03.02
하회
-53.8%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+266.1%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 51.6% · Top tier
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+904.3%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 33.7% · Top tier
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+35.2%
우수
My positionTop 25%
Low range Average High range
초고성장주 소형주 Median 6.9% · Top 22%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-1.5%
평균
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 7.0% · Bottom 40%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+41.0%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 32.4% · Top 38%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-7.6%
부진
My positionBottom 25%
Low range Average High range
초고성장주 소형주 Median 14.5% · Bottom 18%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Outperformed the market by 260%p over 5 years
HROW +328.1% · S&P 500 +68.4%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
+259.8%p
well ahead of the market
vs Health Care (XLV)
+303.6%p
well ahead of the sector average
1-year basis
vs S&P 500
-12.5%p
behind the market
vs Health Care (XLV)
-16.2%p
behind the sector average
Rank among peers
5-year return Top among peers Based on 25 peers
1-year return Upper-Mid (49%) Based on 28 peers
Current position within 52-week range
Low (-31.3%p) High (-31.7%p)
Current price is 31.3% above the 52-week low and 31.7% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-46.3%
Annualized volatility
77.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵
Current diagnosis · 2026-07-27
Oversold zone — rebound potential

Current price $37.46 fell below the lower band ($38.45). Selling pressure excessive; worth watching for a short-term bounce. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 0.179 · Signal 1.086 · Hist -0.907. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 37.8 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 1.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Assets·Vs. Sales·Vs. Cash Flow, In line with peers on Vs. Earnings
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Mid-range
🏢 Vs. Assets Pricey
🧾 Vs. Sales Pricey
💧 Vs. Cash Flow Pricey
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
16.04x
✓ Fair
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 10.48x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
48.63x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Bottom 1% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
5.20x
✓ Pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Bottom 20% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
33.18x
✓ Pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 9.45x · Bottom 16% — expensive within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
97.71x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 9.25x · Bottom 1% — expensive within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$67.75 vs. current price +80.9%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 소형주

Who owns it?

Ownership backdrop is unfavorable
Insider modest net selling -3.1% · Institutional modest net selling -0.3% · Short interest very high 21.8% · Short interest up +4.5pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-3.1%
Insiders net selling
🏦 Institutions (funds & investors)
-0.3%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 57.8%
Adequate institutional weight
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 15.7%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 26.5%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
21.8%
Very high — strong short-side pressure
Healthcare 소형주 Median 11.2%
Past 90 days 📈 +4.5%p increase
Short interest days to cover
8.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 37.3M주
Float (tradable shares) 31.4M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding HROW

ETFs with the highest weightings · 10 total shown
XPH
XPH
State Street SPDR S&P Pharmaceuticals ETF
1.83%
$475M
PILL
PILL
Direxion Daily Pharmaceutical & Medical Bull 3X ETF
1.47%
$21M
FDHY
FDHY
Fidelity Enhanced High Yield ETF
0.70%
$566M
DWAS
DWAS
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
$434M
IHE
IHE
iShares U.S. Pharmaceuticals ETF
0.32%
$1.6B
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
HROW HROW This Stock
$1.4B- 48.6 ▼-35.14% ▲- -2.6%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
해로우(HROW) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
해로우 HROW는 안과 전문 제약 기업으로, ImprimisRx 조제 사업과 안과 의약품 포트폴리오를 기반으로 매출 성장이 이어지고 있습니다. 안과 시장 집중 전략과 함께 HROW 주가 전망 및 실적 흐름을 살펴봅니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 하로우(HROW)?

하로우(HROW) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of HROW?

The market cap of HROW is approximately $1.4B, ranking 2,396 within its sector.

What is the 52-week high and low for HROW?

HROW has recorded a 52-week high of $54.85 and a low of $28.54.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.